

#4

COPY OF PAPERS
ORIGINALLY FILED



Attorney Docket No.: 5386.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al.

Application No.: 10/083,058

Group Art Unit: 1653

Filed: February 25, 2002

Examiner: To Be Assigned

For: Aggregates of Human Insulin Derivatives

Confirmation No. 6987

RECEIVED

SEP 05 2002

TECH CENTER 1600/2900

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the June 27, 2002 Notice to Comply With Sequence Requirements (copy attached), please amend the specification as follows:

IN THE SPECIFICATION:

Please substitute the following amended paragraphs in the specification for the original paragraphs at the same location:

At page 6, lines 11-12, please insert the following:

-- a) the residues B24-B30 (SEQ ID NO:1) of the B-chain of the insulin derivative is the sequence Phe-X-X- X-X-X-X, where each X independently represents any codable amino acid or a deletion;--

At page 6, lines 13-14 please insert the following:

-- a) the residues B25-B30 (SEQ ID NO:2) of the B-chain of the insulin derivative is the sequence Phe-X-X-X- X-X, where each X independently represents any codable amino acid or a deletion;--

At page 6, lines 15-16, please insert the following:

-- c) the residues B26-B30 (SEQ ID NO:3) of the B-chain of the insulin derivative is the

sequence Tyr-X-X-X-X, where each X independently represents any codable amino acid or a deletion;--

At page 6, lines 17-18, please insert the following:

- d) the residues B27-B30 (SEQ ID NO:4) of the B-chain of the insulin derivative is the sequence Thr-X-X-X, where each X independently represents any codable amino acid or a deletion;--

REMARKS

Applicants enclose herewith a paper copy of the Sequence Listing for the above-captioned application. The computer-readable form in this application is identical with that filed on October 5, 2001 in parent application serial no. 09/227,774 filed January 8, 1999. In accordance with 37 CFR 1.821(e), please use the computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application.


I hereby state that the content of the attached paper copy of the Sequence Listing and of the diskette copy of the Sequence Listing filed in the parent application, submitted in accordance with 37 C.F.R. § 1.821(c) and (e) respectively, are the same.

The specification has been amended to provide SEQ ID NOS for the sequences disclosed in the Sequence Listing. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: August 27, 2002


Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

1653

COPY OF PAPERS
ORIGINALLY FILED

PATENT



Attorney Docket No.: 5386.224-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al

Serial No.: 10/083,058

Group Art Unit: 1653

Filed: February 25, 2002

Examiner: To be assigned

Confirmation No.: 6987

For: Aggregates of Human Insulin Derivatives

RECEIVED

SEP 05 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to Comply with Sequence Requirements
2. Copy of Notice to Comply with Sequence Rules
3. Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence
Commissioner for Patents
Washington, DC 20231

on August 27, 2002.

Maya Faison-Phillip
(name of person mailing paper)

Maya Faison-Phillip
(signature of person mailing paper)



"Marked Up" Version Of Amendments To The Specification

At page 6, lines 11-12, please insert the following:

-- a) the residues B24-B30 (SEQ ID NO:1) of the B-chain of the insulin derivative is the sequence Phe-X-X- X-X-X-X, where each X independently represents any codable amino acid or a deletion;--

At page 6, lines 13-14, please insert the following:

-- a) the residues B25-B30 (SEQ ID NO:2) of the B-chain of the insulin derivative is the sequence Phe-X-X-X- X-X, where each X independently represents any codable amino acid or a deletion;--

At page 6, lines 15-16, please insert the following:

-- c) the residues B26-B30 (SEQ ID NO:3) of the B-chain of the insulin derivative is the sequence Tyr-X-X-X-X, where each X independently represents any codable amino acid or a deletion;--

At page 6, lines 17-18, please insert the following:

-- d) the residues B27-B30 (SEQ ID NO:4) of the B-chain of the insulin derivative is the sequence Thr-X-X-X, where each X independently represents any codable amino acid or a deletion;--

**COPY OF PAPERS
ORIGINALLY FILED**

RECEIVED
SEP 05 2002
TECH CENTER 1600/2900

2/9

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

SEP 15 2002

W



UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov


APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/083,058	02/25/2002	Svend Havelund	5386.224-US

Reza Green, Esq.
Novo Nordisk of North America, Inc.
Suite 6400
405 Lexington Avenue
New York, NY 10174-6401



CONFIRMATION NO. 6987

FORMALITIES LETTER



OC000000008366211

Date Mailed: 06/27/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*